IKT
Inhibikase Therapeutics Inc

1,938
Mkt Cap
$218.28M
Volume
8.87M
52W High
$2.46
52W Low
$1.33
PE Ratio
-3.16
IKT Fundamentals
Price
$1.80
Prev Close
$1.83
Open
$1.84
50D MA
$1.78
Beta
1.09
Avg. Volume
3.35M
EPS (Annual)
-$1.16
P/B
1.85
Rev/Employee
$0.00
$20.37
Loading...
Loading...
News
all
press releases
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Rating of "Buy" by Analysts
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has received a consensus recommendation of "Buy" from the six ratings firms that are presently covering the firm, Marketbeat Ratings...
MarketBeat·11d ago
News Placeholder
More News
News Placeholder
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded to "Strong-Buy" at LADENBURG THALM/SH SH
LADENBURG THALM/SH SH upgraded Inhibikase Therapeutics to a "strong-buy" rating in a report on Wednesday...
MarketBeat·17d ago
News Placeholder
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Short Interest Update
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 13th, there was short interest totaling...
MarketBeat·18d ago
News Placeholder
Inhibikase Therapeutics (NYSE:IKT) Coverage Initiated at LADENBURG THALM/SH SH
LADENBURG THALM/SH SH initiated coverage on Inhibikase Therapeutics in a research report on Wednesday. They set a "buy" rating and a $4.00 target price for the company...
MarketBeat·18d ago
News Placeholder
FY2025 Earnings Forecast for IKT Issued By Lifesci Capital
Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) - Stock analysts at Lifesci Capital issued their FY2025 earnings per share estimates for Inhibikase Therapeutics in a report issued on Monday...
MarketBeat·24d ago
News Placeholder
Inhibikase Therapeutics (NYSE:IKT) Trading Up 4.4% - Still a Buy?
Inhibikase Therapeutics (NYSE:IKT) Stock Price Up 4.4% - Time to Buy...
MarketBeat·25d ago
News Placeholder
Inhibikase Therapeutics (NASDAQ:IKT) Upgraded by Lifesci Capital to "Strong-Buy" Rating
Lifesci Capital raised Inhibikase Therapeutics to a "strong-buy" rating in a report on Monday...
MarketBeat·25d ago
News Placeholder
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Receives Consensus Rating of "Buy" from Analysts
Inhibikase Therapeutics, Inc. (NASDAQ:IKT - Get Free Report) has been given a consensus recommendation of "Buy" by the five research firms that are currently covering the stock, Marketbeat Ratings...
MarketBeat·1mo ago
News Placeholder
Inhibikase Therapeutics (NASDAQ:IKT) Trading Up 6.9% - Time to Buy?
Inhibikase Therapeutics (NASDAQ:IKT) Trading 6.9% Higher - Still a Buy...
MarketBeat·1mo ago
News Placeholder
Inhibikase Therapeutics (NYSE:IKT) Earns Buy Rating from Analysts at Bank of America
Bank of America initiated coverage on shares of Inhibikase Therapeutics in a research report on Wednesday. They set a "buy" rating and a $6.00 price target on the stock...
MarketBeat·2mo ago
<
1
2
...
>

Latest IKT News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.